Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
agilon health, inc. filings document the company’s value-based healthcare services business, governance matters, capital structure and operating results. Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, executive appointment and compensation arrangements, and material definitive agreements, including amendments to the company’s credit agreement.
Definitive proxy statements cover shareholder voting matters, board governance and executive compensation. The filing record also includes capital-structure disclosures, such as a certificate amendment related to a reverse stock split of common stock, along with risk-factor and material-event disclosures relevant to agilon’s physician-partnership model and payor contracting environment.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported two Form 4 transactions in Common Stock. On April 15, 2026, 122 shares were withheld at $26.88 per share, and on April 14, 2026, 25 shares were withheld at $22.68 per share to satisfy tax obligations from restricted stock unit settlements. These transactions did not involve open-market sales, and Gertsch held 14,177 shares of Common Stock directly after the most recent transaction.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported two small share dispositions that were solely for tax withholding. On April 15, 2026, 571 shares of Common Stock were withheld at $26.88 per share, leaving 122,850 shares held directly. On April 14, 2026, 104 shares were withheld at $22.68 per share, after which he held 123,421 shares. A footnote explains these were shares withheld by the issuer to satisfy income tax obligations in connection with net settlement of restricted stock units and do not represent open-market sales.
agilon health, inc. reported that its Chief Financial Officer, Jeffrey A. Schwaneke, received a grant of 75,000 shares of Common Stock in the form of restricted stock units on April 1, 2026. These restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
On the same date, 1,662 shares of Common Stock were withheld by the company to cover income tax obligations related to the net settlement of restricted stock units, and this did not represent an open-market sale. After these transactions, Schwaneke directly beneficially owned 140,342 shares, which include restricted stock units, and indirectly beneficially owned 892 shares held by a trust. The reported beneficial ownership amounts reflect a 1-for-25 reverse stock split of agilon health’s common stock that became effective on March 30, 2026.
agilon health, inc. reported that Chief Markets Officer Benjamin Shaker received a grant of 70,000 shares of Common Stock in the form of restricted stock units at $0.00 per share. On the same date, 1,664 shares were withheld at $9.75 per share to cover income tax obligations, and this did not represent an open-market sale.
After these transactions, Shaker beneficially owned 123,525 shares of Common Stock, which includes restricted stock units and reflects a 1-for-25 reverse stock split effective March 30, 2026. The restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported equity compensation and related tax withholding in Common Stock. He received 10,000 restricted stock units that vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
On the same date, 266 shares of Common Stock were withheld by the company to cover income tax obligations tied to the RSU net settlement; this was a tax-withholding disposition and not an open-market sale. Following these transactions, Gertsch beneficially owned 14,324 shares, a figure that reflects the issuer’s 1-for-25 reverse stock split effective March 30, 2026 and includes RSUs.
agilon health, inc. Chief Technology Officer Venkatachaliah Girish reported routine equity compensation and related tax withholding in company stock. On April 1, 2026, he received a grant of 28,000 shares of Common Stock, described as restricted stock units that vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment. On the same date, 480 shares at $9.75 per share were withheld by the issuer solely to satisfy income tax obligations in connection with the net settlement of restricted stock units and do not represent a sale. Following these transactions, his beneficial ownership increased to 38,662 shares, which the disclosure notes reflects a 1-for-25 reverse stock split of the company’s common stock effective March 30, 2026.
agilon health, inc. Chief Legal Officer Denise Zamore reported routine equity compensation and related tax withholding. She received a grant of 50,000 shares of Common Stock on a grant/award basis, increasing her direct beneficial ownership to 66,837 shares, which includes restricted stock units.
On the same date, 1,024 shares of Common Stock were withheld by the company at $9.75 per share to cover income tax obligations from the net settlement of restricted stock units, and this did not represent an open-market sale. The filing notes a 1-for-25 reverse stock split of agilon health’s common stock effective March 30, 2026, and states that the reported holdings reflect this adjustment. The restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
agilon health, inc. implemented a 1-for-25 reverse stock split of its common stock, effective at 4:36 p.m. Eastern Time on March 30, 2026. Every 25 previously issued or treasury shares were automatically reclassified into one new share, with no action required from stockholders.
No fractional shares will be issued; holders entitled to fractions will receive cash instead. Proportional adjustments were made to shares and exercise prices under equity incentive plans and outstanding equity awards. The split does not change the number of authorized common shares or the $0.01 par value. Split-adjusted trading on the NYSE under the symbol AGL begins March 31, 2026.
agilon health, inc. is implementing a 1-for-25 reverse stock split of its common stock after stockholders approved an amendment to its certificate of incorporation at a special meeting. The proposal passed with 356,574,789 votes for, 6,187,388 against and 365,864 abstentions.
The reverse split is expected to become effective on March 30, 2026, around 5:00 p.m. Eastern Time, with split-adjusted trading on the NYSE beginning March 31, 2026 under the symbol AGL. After the change, every 25 shares will be combined into one share, resulting in approximately 16,605,993 shares outstanding.
The company states the reverse split is intended to increase its share price above $1.00 to meet NYSE minimum bid requirements and potentially improve the marketability and liquidity of the stock. No fractional shares will be issued; holders entitled to fractions will receive cash instead, and equity awards and related instruments will be adjusted proportionally.
agilon health, inc. Chief Legal Officer Denise Zamore reported equity compensation activity tied to performance-based restricted stock units (PSUs). An award granted on April 14, 2023 fully vested on March 9, 2026 after agilon health achieved 42% of predetermined Revenue and Adjusted EBITDA goals over the three-year period from January 1, 2023 through December 31, 2025.
Each vested PSU settled into one share of common stock, resulting in 5,535 shares reported as acquired. In connection with this net settlement, 2,056 shares of common stock were withheld by the company at $0.5999 per share to satisfy income tax withholding and remittance obligations, which the disclosure notes does not represent a sale. Following these transactions, Zamore directly holds 446,604 shares of common stock, a figure that includes restricted stock units.